Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Entheon Biomedical Corp C.ENBI

Alternate Symbol(s):  ENTBF

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is interested in treating addiction and substance-use disorders.

CSE:ENBI - Post Discussion

Entheon Biomedical Corp > ENBI: Private Placement
View:
Post by Adstock on Dec 23, 2020 11:05pm

ENBI: Private Placement

Can’t understand the reason for this private placement at such a ridiculous price with half a warrant already at-the-money! Unnecessary dilution for a company that had no need for cash in the near term. What is there to take from this? Lack of confidence or special (if not specific) request from institutions. Why did the OSC allow such a deal? Makes no sense and makes a lot of small investors very upset. Please explain!
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities